Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.51 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.51 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | LOX | P28300 | 4/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28379952 | 0.98 | NPSR1 (0.50) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL2412998 | 0.86 | HPGD (0.50) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| Hydrochloric Acid SCHEMBL2410455 | 0.84 | HPGD (0.49) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL11984343 | 0.83 | HPGD (0.56) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL1401544 | 0.83 | LMNA (0.53) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL2160994 | 0.83 | HPGD (0.51) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL2160349 | 0.82 | HPGD (0.54) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| Hydrochloric Acid SCHEMBL5725652 | 0.82 | HPGD (0.50) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL348559 | 0.81 | LMNA (0.51) | NPSR1LMNAPPARGNCOA2NCOA1 | |
| SCHEMBL14135378 | 0.81 | LMNA (0.51) | NPSR1LMNAPPARGNCOA2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-09-08 | — | — | US | disclosed |
| WO-2020227097-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-2528908-B1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | ALLERGAN INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9090584-B2 | Therapeutic agents for treatment of ocular hypertension | ALLERGAN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2528908-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | Allergan, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011094231-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20110184055-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | ALLERGAN, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7795245-B2 | Heterobicyclic metalloprotease inhibitors | Atlantos Pharmaceuticals Holding, Inc. (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2008115281-A2 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | HOCHGURTEL MATTHIAS | 2008-09-11 | — | — | US | disclosed |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | MYRIAD GENETICS, INCORPORATED (US) | 2008-08-28 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2008002671-A2 | METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-4410532-A | N-Substituted aziridine-2-carboxylic acid derivatives and their immuno-stimulation compositions and methods | BOEHRINGER MANNHEIM GMBH (DE) | 1983-10-18 | — | — | US | disclosed |
| US-4409236-A | N-Substituted aziridine-2-carboxylic acid derivatives and immuno-stimulation composition and method | BOEHRINGER MANNHEIM GMBH (DE) | 1983-10-11 | — | — | US | disclosed |
| US-4321194-A | N-Substituted aziridine-2-carboxylic acid derivatives for immuno stimulation | BOEHRINGER MANNHEIM GMBH (DE) | 1982-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280476-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | NPSR1 2433/4885LMNA 1423/4885PPARG 4045/4885 |
| US-20080221083-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | NPSR1 2291/4885LMNA 2478/4885PPARG 3554/4885 |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | NPSR1 154/4885LMNA 4640/4885PPARG 720/4885 |
| US-20110184055-A1 | THERAPEUTIC AGENTS FOR TREATMENT OF OCULAR HYPERTENSION | PTGIR, PTGIS, AGTR2 | NPSR1 1074/4885LMNA 3581/4885PPARG 419/4885 |
| US-20080207573-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | NPSR1 2311/4885LMNA 2353/4885PPARG 487/4885 |
| US-20110144069-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, CCL11 | NPSR1 2311/4885LMNA 2353/4885PPARG 487/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | NPSR1 991/4885LMNA 2158/4885PPARG 3162/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | NPSR1 2352/4885LMNA 2387/4885PPARG 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.